Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track MXCT with free AI briefings, catalyst countdowns, and dilution alerts.

MXCT · MaxCyte, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$105.7M Cash, Jun 2026

49mo Cash Runway (est.)

-3% Share Count, 1 Year

Follow MXCT by email Get an email when MXCT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MXCT, unsubscribe in one click. Privacy

📣 What MXCT Says Is Next

this year · “The SPL portfolio continues to advance in the clinic, including a clinical customer that began dosing patients in a registrational study in the first quarter, and we remain confident additional customers will initiate registrational trials this year.”
Company press release, May 12, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

💰 Cash Runway & Dilution Risk

MXCT reported $105.7M in cash and short-term investments (as of Jun 30, 2026) and used about $6.5M/quarter in operations, an estimated runway of 49 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Cash runway 49 months

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MXCT files for a raise →

Get the full MXCT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MXCT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z